Last update 29 Nov 2024
Semaglutide biosimilar(QL Biopharma)
Last update 29 Nov 2024
Overview
Basic Info
Drug Type Recombinant polypeptide, Biosimilar |
Synonyms Semaglutide Biosimilar (Beijing Zhitai Biomedical Technology Co., Ltd.), Semaglutide biosimilar(Tonghua Dongbao Pharmaceutical Co., Ltd.), 司美格鲁肽 生物类似药（Beijing Zhitai Biomedical Technology Co., Ltd.） + [5] |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 50953
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Semaglutide biosimilar(QL Biopharma)在二甲双胍治疗后血糖控制不佳的2型糖尿病患者中比较 ZT001注射液与诺和泰®皮下注射治疗的疗效和安全性：一项多中心、随机、开放、平行对照Ⅲ期临床试验
[Translation] Comparison of the efficacy and safety of ZT001 injection and Novotel® subcutaneous injection in patients with type 2 diabetes with poor glycemic control after metformin treatment: a multicenter, randomized, open, parallel-controlled phase III clinical trial
在中国男性健康受试者中比较 ZT001 和诺和泰®注射液的药代动力学特征、
安全性和免疫原性的单中心、随机、开放、平行对照的 I 期临床研究
[Translation] A single-center, randomized, open-label, parallel-controlled Phase I clinical study comparing the pharmacokinetic characteristics, safety and immunogenicity of ZT001 and Novotai® injection in healthy Chinese male subjects
100 Clinical Results associated with Semaglutide biosimilar(QL Biopharma)
Login to view more data
100 Translational Medicine associated with Semaglutide biosimilar(QL Biopharma)
Login to view more data
100 Patents (Medical) associated with Semaglutide biosimilar(QL Biopharma)
Login to view more data
100 Deals associated with Semaglutide biosimilar(QL Biopharma)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cardiovascular Diseases | Phase 3 | CN | 18 Jul 2024 | |
| Diabetes Mellitus, Type 2 | Phase 3 | CN | 18 Jul 2024 | |
| Myocardial Infarction | Phase 1 | CN | 26 Apr 2023 | |
| Stroke | Phase 1 | CN | 26 Apr 2023 | |
| Obesity | IND Approval | CN | 12 Oct 2024 | |
| Obesity | IND Approval | CN | 12 Oct 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free